|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Xenografts**  | **Membrane Scoreb**  | **Heterogeneous Expression**  | **Dose (mg/Kg)**  | **TVI (%)c**  |
| HPAFII  | 3+  | HO  | 5  | 96  |
| AsPc-1  | 0  | nd  | 5  | 0  |
| HCC-1806  | 1+  | HO  | 3.5  | 92.7  |
| HCC-70  | 1+  | HO  | 2.5  | 98  |
| SW780  | 2+  | HO  | 5  | 97  |
| PC-PDX6Pa  | 3+  | HO  | 5  | 77.3  |
| PDX21a  | 1+  | HO  | 5  | 77.5  |
| PDX347a  | 3+  | HO  | 5  | 94.7  |
| PDX22a  | 1+  | HO  | 5  | 50  |
| CTG-1388a  | 2+  | HE  | 5  | 50  |
| CTG-1652a  | 2+  | HE  | 5  | 37.7  |

Supplementary Table S4

**Supplementary Table S4:** Antitumor activity of MEN1309/OBT076 on xenograft and PDX models with different CD205 antigen expression. a) PDX models.b) Score indicate the staining intensity. HE = heterogeneous. HO = homogeneous. c) TVI%, tumor volume inhibition, expressed as a percentage, indicates the ratio % between the mean of the tumor volume of the test article-treated group and the control treated with drug vehicle calculated at the Nadir of tumor growth.